Helen E. Remotti, MD

Board Certifications: 
Pathology-Anatomic/Pathology-Clinical
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Liver Pathology

Academic Appointments

  • Associate Professor of Pathology & Cell Biology at CUMC

I joined the division of Surgical Pathology in the Department of Pathology and Cell Biology at Columbia University as a faculty member in 2002. One of my primary functions as a surgical pathologist at Columbia University involves providing diagnostic expertise in diverse areas of pathology from clinical cases with a high level of complexity. I serve as a senior consultant pathologist, with a focused interest in pancreatic, hepatic and gastrointestinal pathology. At Columbia University this subspecialty includes a wide spectrum of diagnostically challenging cases encompassing transplant pathology (liver, small intestine, pancreas), adult and pediatric medical liver disease, and oncologic pathology.

As a member in the division of Personalized Genomics as of 2016, I have been involved in molecular profiling studies examining a variety of types of pediatric hepatobiliary and gastrointestinal tumors. Since 2014, I have been involved in the Precision in Pediatrics (PIPseq) Cancer initiative, and have been working closely with members in the Division of Pediatric Hematology/ Oncology, primarily focusing on molecular studies involving pediatric liver tumors and neuroblastomas. Due to the expertise of our liver surgeons and orthotopic liver transplantation program, and our pediatric oncologists we see an over representation of high risk pediatric hepatic tumors. In collaboration with the Herbert Irving Cancer Center Tumor bank, for these studies we have an established a hepatic tumor pathology database with tissue microarrays and examined a variety of immunohistochemical and molecular biomarkers in subsets of these tumors. These studies may offer patients the possibility of entry into clinical trials that will enable the use of novel targeted drug therapies, particularly in classes of tumors unresponsive to conventional treatment modalities.  

Email: her2007@cumc.columbia.edu

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, Northwestern University Feinberg School of Medicine
  • Residency: University of California Los Angeles Medical Center
  • Fellowship: Armed Forces Institute

Board Certifications

  • Pathology-Anatomic/Pathology-Clinical

Research

Grants

THE DEVELOPMENT AND PROGRESSION OF IPMN TO PDA IN THE CONTEXT OF INACTIVATED ACTIVIN SIGNALING (Federal Gov)

Mar 15 2017 - Feb 28 2022

THE ROLE OF WILD-TYPE KRAS IN THE CONTEXT OF TUMOR PROGRESSION AND METASTASIS (Federal Gov)

May 1 2015 - Apr 30 2020

THE SAFETY OF RED BLOOD CELL TRANSFUSIONS (Federal Gov)

Jul 1 2014 - Dec 31 2018

ROLE OF NEURONS IN THE DEVELOPMENT AND PROGRESSION OF PANCREATIC CANCER (Private)

Jan 1 2013 - Dec 31 2016